Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma

Morobeid, Heba; Pizarro, Carmen; Biener, Leonie; Kütting, D; Nickenig, Georg; Skowasch, Dirk

doi:10.1183/23120541.00190-2021

Cited by 8 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…16 A single-center, observational cohort study from Germany found that antibody treatments (including mepolizumab), when added to standard asthma therapies, were as efficacious in ex-smokers suffering from severe asthma as they are in nonsmokers, by improving the asthma control, exacerbation rate and lung function of these patients. 37 Evaluations from a number of other real-world databases also underscore the importance of everyday clinical experience with mepolizumab. The findings provide efficacy results that are similar to the GAN data and the results from controlled clinical trials.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

Korn¹,

Milger²,

Skowasch³

et al. 2023

JAA

Self Cite

View full text Add to dashboard Cite

Purpose The German Asthma Net (GAN) operates a Severe Asthma Registry that provides an overview of the clinical presentation and management of patients with severe asthma. Based upon data from the GAN registry, the MepoGAN study aimed to describe clinical profiles and treatment outcomes of patients who were treated with the anti-IL-5 monoclonal antibody mepolizumab (Nucala TM ) in routine practice in Germany. Patients and Methods The MepoGAN study is a descriptive retrospective non-interventional cohort study. Mepolizumab patients enrolled in the GAN registry were evaluated with results being described in two different data sets: Cohort 1 (n=131) started on mepolizumab when the patients entered the registry. Results were reported after 4 months of therapy. Patients in Cohort 2 (n=220) were on treatment with mepolizumab at the time of enrollment and follow-up data were collected after a further year of treatment. Outcome measures included asthma control, lung function, disease symptoms, OCS use, and exacerbations. Results Patients enrolled in the registry who started on mepolizumab in Cohort 1 had a mean age of 55 years, were former smokers in 51% of the cases, had a mean blood eosinophil count of 500 cells/μL, and frequently had maintenance OCS use (55%). In this real-world setting, mepolizumab therapy was associated with a clinically relevant reduction in blood eosinophils (−445.7 cells/μL), OCS use (−30%), and improvement in asthma control. Fifty-five percent (vs 10% at baseline) of the patients reported controlled or partially controlled asthma 4 months after starting therapy. In patients who were already treated with mepolizumab at registry enrollment (Cohort 2), asthma control and lung function remained stable after a further year of observation. Conclusion The GAN registry data confirm the effectiveness of mepolizumab in a real-world setting. Treatment benefits are maintained over time. While the asthma of patients treated in routine practice was more severe, the results observed with mepolizumab are broadly consistent with RCTs.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

Korn¹,

Milger²,

Skowasch³

et al. 2023

JAA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our study results confirm recent findings by M orobeid et al . [ 30 ] analysing antibody treatment in patients with allergic or eosinophilic asthma and a smoking status of >10 PY, showing treatment efficacy of IL-5 antibodies. In contrast to our study only limited information concerning patient characteristics were provided, not allowing further phenotyping of patients.…”

Section: Discussionmentioning

confidence: 99%

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD

et al. 2022

View full text Add to dashboard Cite

BackgroundAnti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies represents an established treatment for patients with severe eosinophilic asthma (SEA) but did not show clinical efficacy in patients with chronic obstructive pulmonary disease (COPD).ObjectiveTo evaluate treatment response to anti-eosinophilic antibody therapy in patients with Asthma and COPD.MethodsA retrospective comparison of pulmonary function testing, oral corticosteroid intake, quality of life and pulmonary symptom control in patients with SEA and COPD and 1:1 propensity score matched patients suffering from SEA alone was performed. All patients received treatment with either mepolizumab or benralizumab. Data were assessed prior to antibody treatment start and after 6 months of therapy.ResultsData from 84 patients (42 patients with SEA and COPD and 42 patients with SEA) were analysed. After 6 months of treatment, patients in both groups showed improved forced expiratory volume in one second (improvement by 11% [IQR 5; 18] in the SEA and COPD group versus 15% [IQR −3; 23]; p=0.637) and decreased oral corticosteroid dosages (median reduction by 3 mg in the SEA and COPD group versus 5 mg; p=0.070), without significant differences between groups. Pulmonary symptom control and quality of life improved in both groups. A significant decrease in eosinophils could be measured in both groups with similar cell numbers prior to treatment initiation (600 cells µL−1 in the SEA and COPD group versus 500 cells µL−1).ConclusionAnti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies shows clinical efficacy in patients with SEA and COPD comparable to treatment response in patients with SEA alone.

show abstract

Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register

Baastrup Soendergaard,

Hansen,

Bjerrum

et al. 2024

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma

Cited by 8 publications

References 14 publications

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD

Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register

Contact Info

Product

Resources

About